Page 27 - Mployee Wellness Programs News Today

Astellas Pharma’s zolbetuximab was on track to become the first gastric cancer drug that targets claudin 18.1, a protein found on cancerous stomach cells. Others with clinical-stage programs addressing this this target include AstraZeneca and Bristol Myers Squibb.

Commons Clinic — a value-based physician group providing musculoskeletal care to patients in the Los Angeles area — announced the launch of its Center for Spine Economics, Outcomes & Research. The center will research and test new models that move spinal care out of the hospital and into community-based accountable care networks. The startup plans to invest $100 million in the center over the next decade.

A decade after the first recreational marijuana dispensaries opened, will 2024 be the year that cannabis finally gets a get-out-of-jail-for-free card?

Elevance Health will provide smartphones with unlimited data, talk and text to some Medicaid members in 2024, it announced at CES 2024.

In 2023, digital health fundraising took on a bit of a different shape, according to a new Rock Health report. Startups tried out some creative ways to keep their businesses afloat — including series extension rounds, unlabeled fundraises and silent deals from existing investors.

From its heady unicorn days to being newly public to its current financial struggles, the portable ultrasound-on-a-chip company has seen it all. Now, its latest CEO has his work cut out for him. A return to revenue growth is what Joseph DeVivo is promising this year.

This year, ViVE will celebrate nurses throughout the event's programming, highlighting how their role has evolved, the challenges they face and how they are spurring innovation in different models of care. The event is powered by HLTH and the College of Healthcare Information Management Executives (CHIME).

The hospital sector's financial performance in November showed signs of continued stabilization and growth, according to Kaufman Hall’s latest monthly report. Hospitals should "take advantage of the relative stability and re-embrace strategic growth if they hope to see continued success in 2024," stated Erik Swanson, one of the report's authors.

Though GSK divested much of its oncology assets to Novartis in 2015, the company has built it back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.

XRHealth's $6 million in funding was led by Asabys Partners and included participation from NOVA Prime Fund. The company will use the funding to support its recent merger with Amelia Virtual Care.